Aron Bercz,Daniel L Faden,J Joshua Smith,Paul B Romesser
{"title":"Clocking Recurrence: Circulating Tumor HPV DNA Kinetics in Anal Cancer.","authors":"Aron Bercz,Daniel L Faden,J Joshua Smith,Paul B Romesser","doi":"10.1158/1078-0432.ccr-25-0421","DOIUrl":null,"url":null,"abstract":"Detection of circulating tumor human papillomavirus DNA (ctHPVDNA) three months after completing definitive chemoradiation for localized anal squamous cell carcinoma associates with disease recurrence and inferior recurrence-free survival. These findings provide valuable insights into the temporal significance of ctHPVDNA detection in anal cancer and its potential implications for early intervention.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"116 1","pages":""},"PeriodicalIF":10.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.ccr-25-0421","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Detection of circulating tumor human papillomavirus DNA (ctHPVDNA) three months after completing definitive chemoradiation for localized anal squamous cell carcinoma associates with disease recurrence and inferior recurrence-free survival. These findings provide valuable insights into the temporal significance of ctHPVDNA detection in anal cancer and its potential implications for early intervention.
期刊介绍:
Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.